Compare Garmin Ltd. (GRMN) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Twist Bioscience Corp — how do they compare? Garmin Ltd. trades at $271.28 (market cap $53.26B), while Twist Bioscience Corp trades at $157 (market cap $10.32B). The key difference: Garmin Ltd. is far larger — about 5.2× Twist Bioscience Corp's market cap, and Garmin Ltd. pays a 1.52% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and Twist Bioscience Corp for 27 Days on average.
| GRMN | TWST | |
|---|---|---|
Market Cap | $53.26B | $10.32B |
Volume | 529,054 | 5,894,998 |
Sector | Technology | Health |
52-Week High | $313.16 | $205.00 |
52-Week Low | $187.10 | $25.45 |
Typical Hold Time | 83 Days | 27 Days |
Enterprise Value | $50.77B | $10.24B |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $268.44, down 3.86% on the day, amid a broader bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $2.81 beating estimates of $2.30. Revenue growth remains robust, rising from $4.9B in 2022 to $7.25B in 2025, with net income margins above 20%. Recent positive developments include multiple product awards and new feature rollouts across marine, automotive, and fitness segments.
Garmin presents a compelling investment case with strong profitability and consistent execution, though near-term technical pressure and cautious analyst sentiment (71% hold rating) suggest potential volatility. The consensus price target of $320.25 implies 19% upside, but investors should monitor competitive pressures in the wearable tech space and macroeconomic factors affecting consumer discretionary spending.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
